Document is current
Any future updates will be listed below
-
Authors
Schmidt, Mona W.
Rosin, Anja
Schmidt, Sabine
Steetskamp, Joscha
Linz, Valerie C.
Rodewald, Karin
Schiestl, Lina
Gillen, Katharina
Battista, Marco J.
Stewen, Kathrin
Hasenburg, Annette
Schwab, Roxana
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 19 September 2023
Accepted: 5 March 2025
First Online: 27 March 2025
Declarations
:
: Due to the retrospective analysis of clinical routine data no ethics approval was needed according the State Medical Committee of Rheinland-Pfalz, Germany.
: Not applicable.
: Katharina Anic reports paid lectures by Clovis Oncology, AstraZeneca, Pharma Mar, MSD and Eisai not related to this trial. Marco J. Battista reports honoraria and expenses from Pharma Mar AG, Astra Zeneca, TesaroBio GmbH, GSK, Roche, Clovis Oncology and consultant activity to AstraZeneca, Clovis Oncology, Eisai, GSK, MSD, PharmaMar, Roche and Tesaro Bio GmbH. Furthermore, he has received research funding by AstraZeneca, Clovis Oncology, MSD, Eisai and Novartis. None were related to this study. Annette Hasenburg reports honoraria and expenses from AstraZeneca, Celgen, GSK, Leo Pharma, MedConcept GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Softconsult, Streamedup! GmbH, Roche Pharma AG, Tesaro Bio Germany GmbH as well as work as a consultant to AstraZeneca, GSK, MSD SHARP & DOHME GmbH, PharmaMar, Promedicis, Roche Pharma AG and Tesaro Bio Germany GmbH. None were related to this study. Roxana Schwab reports honoraria and expenses from RochePharma AG, Sanofi and AstraZeneca GmbH. None were related to this study. Mona W. Schmidt, Anja Rosin, Sabine Schmidt, Joscha Steetskamp, Valerie Linz, Karin Rodewald, Lina Schiestl, Katrin Stewen have no conflict of interest or financial ties to disclose.
